David S. Siegel, M.D., Ph.D. and colleagues presented findings from a phase II, single-arm open-label study of carfilzomib (CFZ), a novel, highly selective proteasome inhibitor in development for treatment of advanced multiple myeloma. Proteasome inhibitors block the actions of certain proteins (proteasomes) that cancer cells need to survive and multiply. All patients in the study were previously unresponsive to treatment with other combination therapies. Of 257 patients completing the study, the overall response rate was 24% with a median response duration of 7.4 months. The median overall survival was 15.5 months. CFZ as a standalone treatment achieved significant responses in 36% of patients who did not previously respond to treatment with bortezomib and immunomodulatory drugs, including patients with chromosomal abnormalities. CFZ was well tolerated and adverse events were manageable with no new, unexpected, or cumulative toxicities.
Survival outcomes in elderly patients with plasma cell myeloma: The three-decade Eastern Cooperative Oncology Group (ECOG) experience.
Recent landmark papers showed significant improvement in survival rates for patients under 65 years of age with plasma cell myeloma, but not for older patients. To shed new light on progress in treating older individuals, David H. Vesole, M.D., PH.D., F.A.C.P. and colleagues examined data over the last 33 years for previously untreated patients who were treated according to standard European Cooperative Oncology Group protocols during three time periods: 1988-1993, 1994-2000 and 2001-2006. Patients receiving autologous stem cell transplantation were excluded. For patients over 65 years, there was a higher overall survival in those treated 2001-2006 (39%), than in those treated 1988-1993 and 1994-2000 (2
|Contact: Amy Leahing |
John Theurer Cancer Center